Inhibitors of CREBBP/EP300 bromodomains show promising pre-clinical activity in models of leukemia characterized by the presence of translocations leading to the presence of fusion proteins containing such bromodomains [66,67]. This evidence concerns the gene CREBBP and leukemia.